-
Mashup Score: 0
Ticiana Leal, MD, discusses how tarlatamab, a bispecific T-cell engager (BiTE), leverages the aberrant expression of delta-like ligand 3 on small cell lung cancer (SCLC) cells to direct T-cell-mediated tumor lysis, its promising efficacy shown in the phase 2 DeLLphi-301 study, and the potential clinical benefits of combining it with durvalumab for maintenance therapy after platinum-based chemotherapy.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 10
A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and progression-free survival in extensive-stage small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 8ADRIATIC Study Highlights Survival Gains With Durvalumab in LS-SCLC - 2 month(s) ago
Aakash Desai, MD, MPH, discusses the ADRIATIC study in limited-stage small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Challenging WBRT: SRS Efficacy in SCLC Brain Metastases - 2 month(s) ago
Ayal Aizer, MD, MHS, discussed the changing treatment paradigms of treatment of brain metastases in patients with small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5
During an in-person Community Case Forum event, Ticiana Leal, MD, discussed the trials of lurbinectedin and tarlatalamb as therapy for previously treated small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3Challenging WBRT: SRS Efficacy in SCLC Brain Metastases - 2 month(s) ago
Ayal Aizer, MD, MHS, discussed the changing treatment paradigms of treatment of brain metastases in patients with small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2First Patient with SCLC Dosed With I-DXd in Phase 3 Study - 2 month(s) ago
The phase 3 IDeate-Lung02 study has dosed its first patient with small cell lung cancer with the investigational antibody-drug conjugate infinatamab deruxtecan.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0New Hope on the Horizon for Patients With SCLC - 3 month(s) ago
Ariel Lopez-Chavez, MD, discusses ongoing research in the small cell lung cancer space.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Behind the ADRIATIC Trial in Limited-Stage SCLC - 3 month(s) ago
David Spigel, MD, explains some of the unmet needs for patients with limited-stage small cell lung cancer and how they led to the initiation of the ADRIATIC trial.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
While the primary end point of overall survival was not met in the phase 3 RESILIENT study, the overall response rate was 44.1% vs 21.6% with liposomal irinotecan vs topotecan in relapsed small cell lung cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
Ticiana Leal, MD, discusses tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 in #SCLC, its efficacy in the DeLLphi-301 study, and potential with durvalumab for maintenance therapy. #lcsm | @LealTiciana @WinshipAtEmory https://t.co/25XUA8HjNf